Helicobacter pylori surface proteins and enzymes

Helicobacter pylori surface proteins and enzymes represent a diverse group of molecular targets essential for the survival and pathogenicity of the bacterium (NIH, 2023). The enzyme urease is a primary target, as it neutralizes gastric acid by producing ammonia, a process vital for colonization (StatPearls, 2023). Surface adhesins, including Blood group antigen-binding adhesin (BabA) and Sialic acid-binding adhesin (SabA), facilitate bacterial attachment to the gastric epithelium, while the CagA and VacA proteins act as key virulence factors that disrupt host cell functions (PubMed, 2021; UniProt, 2024). Current treatments utilize antibiotics such as amoxicillin and clarithromycin to target cell wall synthesis and protein translation, respectively (Lancet, 2022). Bismuth subsalicylate is also employed for its ability to inhibit various bacterial enzymes and prevent adhesion (PubMed, 2020). Targeting these surface components is essential for eradicating infections and preventing associated diseases like peptic ulcers and gastric cancer. Understanding these targets is vital for developing new treatments to combat the increasing prevalence of antibiotic-resistant H. pylori strains.

Other names

Helicobacter pylori virulence factorsH. pylori cell surface antigensH. pylori membrane proteinsH. pylori adhesins and enzymes

Antibiotics targeting H. pylori work through several mechanisms: amoxicillin inhibits cell wall peptidoglycan synthesis; clarithromycin and tetracycline inhibit protein synthesis by binding to ribosomal subunits; metronidazole and levofloxacin cause DNA damage or inhibit DNA replication; and bismuth salts exert direct antimicrobial effects by disrupting cell wall integrity and inhibiting enzymatic activities like urease (Lancet, 2022; PubMed, 2020).